
Neuropathic Pain
Neuropathic Pain (NP) represents one of the most difficult types of pain to treat in humans. NP is defined by the IASP as “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system”. It arises from neuronal damage and sensitization within the peripheral and central nervous systems and is characterized by persistent, exaggerated pain responses, including hyperalgesia and allodynia.
Preclinical models of neuropathic pain encompass peripheral nerve injury, chemotherapy-induced peripheral neuropathy, and metabolic neuropathy, recapitulating key etiological mechanisms underlying neuropathic pain in patients.
Models
Chronic Constriction Injury is a discrete peripheral nerve injury model, originally described by Bennett and Xie (1988), that closely relates to post-traumatic or postsurgical neuropathic pain in patients. Loose ligation of the sciatic nerve induces local inflammation and intraneural constriction, producing a unilateral peripheral mononeuropathy.
This results in robust mechanical and cold allodynia, tactile allodynia, and thermal hyperalgesia, with the pain phenotype persisting for at least 84 days. Analgesic potency of test compounds is typically assessed after 14 days post-surgery in rats and after 21 days post-surgery in mice, once the phenotype is fully established.
The model demonstrates pharmacological validity through sensitivity to clinically established treatments — including pregabalin, duloxetine, naproxen, or morphine — establishing it as a robust and widely used preclinical model for evaluating analgesic candidates targeting peripheral neuropathic pain.
Read the full description: Chronic constriction injury (CCI)
Spared Nerve Injury, first described by Decosterd and Woolf (2000), is a model of peripheral mononeuropathy that recapitulates key features of post-traumatic and postsurgical neuropathic pain. It involves ligation and transection of the tibial and common peroneal branches of the sciatic nerve, while the sural nerve is deliberately spared.
This selective denervation produces a long-lasting neuropathy in the sural skin territory, characterized by tactile and cold allodynia that persist for several weeks — a duration well-suited to long-term chronic studies and within-subject test designs. Mechanical hyperalgesia, mechanical allodynia, and tactile allodynia are typically assessed from Day 3 (rats) and Day 7 (mice) post-surgery to assess the analgesic potency of test compounds.
Compared to other partial nerve injury models, SNI is valued for the robustness and reproducibility of its behavioral phenotype, and for preserving an intact nerve territory adjacent to the lesion — a feature that supports mechanistic dissection of injured vs. non-injured afferent contributions to the pain phenotype.
Trigeminal neuralgia is among the most severe forms of NP, characterized by sudden, shock-like pain along the trigeminal nerve (most often the infraorbital branch). It can result from vascular compression, demyelination, or nerve trauma, closely paralleling injury mechanisms modeled preclinically. Transpharmation offers a chronic constriction injury of the infraorbital nerve (ION-CCI) model, reproducing orofacial mechanical/thermal hypersensitivity for robust translational assessment of trigeminal-mediated pain.
Diabetic neuropathy is a leading cause of neuropathic pain in humans, affecting approximately half of diabetic patients as a progressive small fiber neuropathy with both spontaneous and exaggerated evoked pain. Among the various preclinical approaches, the streptozotocin (STZ) model remains the most widely used, owing to its translational value for studying underlying pain mechanisms.
Type 1 diabetes is induced in rats by a single intraperitoneal injection of STZ, which selectively damages insulin-producing pancreatic β-cells. By Day 7, animals present with significant hyperglycemia, weight loss, polydipsia, and polyuria; by Day 14, they exhibit mechanical and thermal allodynia, quantified using both von Frey and cold plate tests.
The resulting painful neuropathy is attenuated by pregabalin, supporting the model’s pharmacological validity for evaluating novel analgesic candidates for diabetic neuropathic pain.
In chemotherapy, cumulative dose-limiting toxicity represents a major problem due to the painful neuropathy induced by antineoplastic agents. When preclinically administered, these chemicals also produce sensory neuropathies consistent with those reported in patients. This is the case with oxaliplatin and paclitaxel-induced hypersensitivity.
Treatment with oxaliplatin or paclitaxel can result in painful peripheral neuropathy, representing a clinically significant dose-limiting toxicity characterized by dysesthesia, paresthesia, and spontaneous pain in the distal extremities. In rodents, both agents induce progressive neuronal degeneration, mechanical hypersensitivity, and cold allodynia through distinct primary mechanisms — DNA-adduct formation and mitochondrial dysfunction for oxaliplatin, microtubule dynamics impairment for paclitaxel. Although their primary mechanisms differ, both involve peripheral alterations, including mitochondrial dysfunction and altered nerve conduction, as well as central mechanisms such as sensitization.
Paclitaxel-induced chronic peripheral sensory neuropathy is modeled via repeated intraperitoneal injections (2 mg/kg x4), with mechanical and cold allodynia.
Oxaliplatin-induced peripheral neuropathy is established in both mice and rats following a single intraperitoneal administration (10 mg/kg), resulting in pronounced mechanical allodynia. In both species, this hypersensitivity is attenuated by pregabalin, supporting the pharmacological validity of these models for the preclinical evaluation of novel analgesic candidates for chemotherapy-induced peripheral neuropathy (CIPN). Both models persist for at least 2–3 weeks.
Read the full description: Chemotherapy-induced neuropathy (Oxaliplatin/Paclitaxel)
Platforms used
Molecular Biomarkers & Histology Molecular biomarkers and tissue biomarker expression
Electroencephalography (EEG) In-vivo rodent telemetry
MoSeq AI-powered motion sequencing
Operant Platform Motivation, impulsivity, attention, cognition, memory
PK/PD Studies Endpoints for lead optimization
PK-Bridge PK studies for discovery budgets
Humanized Models PXB humanized-liver mice
SPIDAR Rapid analgesic screening
Transgenics Genetically modified mice
Have a program in mind?
Talk to a Transpharmation researcher about your study design and timelines.